Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim, Vera Hirsh, Tony S.K. Mok et al. · The Lancet · 2008
Cited by 1,242 works. doi:10.1016/s0140-6736(08)61758-4
Authors
- Edward S. Kim
- Vera Hirsh
- Tony S.K. Mok
- Mark A. Socinski
- R. Gervais
- Yi-Long Lung Cancer Wu
- Long-Yun Li
- Claire L Watkins
- Mark V. Sellers
- Elizabeth Lowe
- Yan Ping Sun
- Mei‐Lin Liao
- Kell Østerlind
- Martin Reck
- Alison A. Armour
- Frances A. Shepherd
- Scott Michael Lippman
- Jean‐Yves Douillard
References
- Global cancer statistics
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Global Cancer Statistics, 2002
- A Sharper Bonferroni Procedure for Multiple Tests of Significance
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Cancer Statistics, 2007
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer